Gilead Sciences, Inc. (GILD) Stock Rating Reaffirmed by William Blair
Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by analysts at William Blair in a research note issued to investors on Thursday. They currently have a $87.00 price target on the biopharmaceutical company’s stock. William Blair’s price target suggests a potential upside of 3.88% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 price target on the stock. in a report on Thursday, May 11th. Stifel Nicolaus reissued a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Wednesday, May 3rd. Gabelli reissued a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a report on Wednesday, May 3rd. Deutsche Bank AG initiated coverage on Gilead Sciences in a research report on Friday, June 23rd. They set a “buy” rating and a $79.00 price objective for the company. Finally, Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Twelve analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $82.26.
Gilead Sciences (GILD) opened at 83.75 on Thursday. The stock has a market capitalization of $109.37 billion, a PE ratio of 9.10 and a beta of 1.18. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $84.13. The stock has a 50 day moving average price of $74.38 and a 200-day moving average price of $69.29.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the firm earned $3.08 earnings per share. On average, equities analysts anticipate that Gilead Sciences will post $8.73 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-william-blair/1537433.html.
In related news, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold 256,666 shares of company stock valued at $19,173,184 in the last three months. 1.30% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of GILD. Intl Fcstone Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $1,110,000. Griffin Asset Management Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $1,151,000. Gs Investments Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $577,000. Paradigm Financial Advisors LLC increased its position in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the period. Finally, RNC Capital Management LLC increased its position in shares of Gilead Sciences by 1.4% in the second quarter. RNC Capital Management LLC now owns 83,702 shares of the biopharmaceutical company’s stock worth $5,924,000 after buying an additional 1,185 shares during the period. 74.04% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.